A Double-Blind, Placebo Controlled-Trial of a Probiotic Strain Lactobacillus sakei Probio-65 for the Prevention of Canine Atopic Dermatitis.
Canine atopic dermatitis (CAD) is a ubiquitous, chronic inflammatory skin disorder prevalent in dogs, which results in production of abnormal levels of IgE antibodies in reciprocation to an allergen challenge. In this study, administration of the probiotic strain Lactobacillus sakei probio-65 for 2 months significantly reduced the disease severity index in experimental dogs diagnosed with CAD. In addition, one month pre-medication of L. sakei probio-65 revealed significant difference in the PVAS score in experimental dogs for both probio-65 and placebo groups. However, post 2 months treatment resulted in a significant decrease in the CASESI score values in the probio-65-treated group (p < .0.06).
Haemaru Referral Animal Hospital, Sungnam 463-050, Republic of Korea.
Hyejin
H
Kim
Department of Applied Microbiology and Biotechnology, Yeungnam University, Gyeongsan 712-749, Republic of Korea.
Irfan A
IA
Rather
Haemaru Referral Animal Hospital, Sungnam 463-050, Republic of Korea.
Hyunwook
H
Kim
Haemaru Referral Animal Hospital, Sungnam 463-050, Republic of Korea.
Sungsoo
S
Kim
Haemaru Referral Animal Hospital, Sungnam 463-050, Republic of Korea.
Taeeun
T
Kim
Haemaru Referral Animal Hospital, Sungnam 463-050, Republic of Korea.
Jaeyoung
J
Jang
Haemaru Referral Animal Hospital, Sungnam 463-050, Republic of Korea.
Jimin
J
Seo
National Science Museum Ministry of Science, ICT and Future Planning, Daejeon 305-705, Republic of Korea.
Jeongheui
J
Lim
Department of Applied Microbiology and Biotechnology, Yeungnam University, Gyeongsan 712-749, Republic of Korea.|proBionic, Yusung, Daejeon 305-333, Republic of Korea.
Yong-Ha
YH
Park
D000818:Animals; D003876:Dermatitis, Atopic / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary*; D004283:Dog Diseases / Q000473:pathology / Q000517:prevention & control*; D004285:Dogs; D004311:Double-Blind Method; D007778:Lactobacillus / Q000254:growth & development*; D010919:Placebos / Q000008:administration & dosage; D019936:Probiotics / Q000008:administration & dosage*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D010919:Placebos
Canine atopic dermatitis; Lactobacillus sakei; probiotics; skin disorder